DK4308114T3 - C5ar1-hæmmere til behandling af overfølsomhedsreaktioner over for taxaner - Google Patents

C5ar1-hæmmere til behandling af overfølsomhedsreaktioner over for taxaner

Info

Publication number
DK4308114T3
DK4308114T3 DK22716203.9T DK22716203T DK4308114T3 DK 4308114 T3 DK4308114 T3 DK 4308114T3 DK 22716203 T DK22716203 T DK 22716203T DK 4308114 T3 DK4308114 T3 DK 4308114T3
Authority
DK
Denmark
Prior art keywords
c5ar1
taxanes
inhibitors
treatment
hypersensitivity reactions
Prior art date
Application number
DK22716203.9T
Other languages
Danish (da)
English (en)
Inventor
Marcello Allegretti
Andrea Aramini
Laura Brandolini
Maria Candida Cesta
Piergiorgio Amendola
Anna Sirico
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21163292.2A external-priority patent/EP4059497A1/en
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Application granted granted Critical
Publication of DK4308114T3 publication Critical patent/DK4308114T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK22716203.9T 2021-03-17 2022-03-17 C5ar1-hæmmere til behandling af overfølsomhedsreaktioner over for taxaner DK4308114T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21163292.2A EP4059497A1 (en) 2021-03-17 2021-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP21217382 2021-12-23
PCT/EP2022/057007 WO2022195017A1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Publications (1)

Publication Number Publication Date
DK4308114T3 true DK4308114T3 (da) 2026-03-23

Family

ID=81307212

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22716203.9T DK4308114T3 (da) 2021-03-17 2022-03-17 C5ar1-hæmmere til behandling af overfølsomhedsreaktioner over for taxaner

Country Status (11)

Country Link
US (1) US20240180888A1 (https=)
EP (1) EP4308114B1 (https=)
JP (1) JP2024512472A (https=)
BR (1) BR112023018826A2 (https=)
CA (1) CA3212816A1 (https=)
DK (1) DK4308114T3 (https=)
FI (1) FI4308114T3 (https=)
HR (1) HRP20260351T1 (https=)
IL (1) IL305727A (https=)
LT (1) LT4308114T (https=)
WO (1) WO2022195017A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025193888A1 (en) * 2024-03-14 2025-09-18 Vanqua Bio, Inc. Pyridazinone c5ar1 antagonists and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1261275A (zh) * 1997-05-27 2000-07-26 巴克·诺顿药物有限公司 给予病人口服紫杉烷类药物的方法和组合物
CA2298475A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
ES2597843T3 (es) 2005-11-24 2017-01-23 Dompé Farmaceutici S.P.A. Derivados de (R)-arilalquilamino y composiciones farmacéuticas que los contienen
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Also Published As

Publication number Publication date
US20240180888A1 (en) 2024-06-06
LT4308114T (lt) 2026-03-25
FI4308114T3 (fi) 2026-03-25
BR112023018826A2 (pt) 2024-03-12
WO2022195017A1 (en) 2022-09-22
HRP20260351T1 (hr) 2026-04-24
EP4308114B1 (en) 2026-02-11
JP2024512472A (ja) 2024-03-19
CA3212816A1 (en) 2022-09-22
EP4308114A1 (en) 2024-01-24
IL305727A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
IL283042A (en) Compounds and compositions for treating conditions associated with nlrp activity
IL292754A (en) Method of synthesis
EP4069212A4 (en) HIF-2 ALPHA INHIBITORS
DK3773593T3 (da) Behandling af hidradenitis suppurativa under anvendelse af JAK-inhibitorer
DK3445767T3 (da) Makrocykliske mcl1-inhibitorer til behandling af cancer
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
IL261015B (en) Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
DK3377516T3 (da) Sammensætning til behandling af cancer
HUE039809T2 (hu) Vegyület karbamid-tartalmú mûtrágyák kezelésére
DK3728410T3 (da) Fremgangsmåde til behandling af lignocelluloseholdig biomasse
DK3331525T3 (da) Anvendelse af CRAC-kanal-inhibitorer til behandling af slagtilfælde og traumatisk hjerneskade
IL287904A (en) Combination treatment of arthritic disease
DK3261726T3 (da) Sammensætning til behandling af acne
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
DK3891145T3 (da) Modulatorer af trex1
DK3573620T3 (da) Sammensætninger til behandling af hypertension
IL282311A (en) Use of reboxetine to treat narcolepsy
DK4447683T3 (da) Anvendelse af isoxazolincarboxamid til hæmning af spiring
SI3833665T1 (sl) Diazabiciklooktanoni kot zaviralci serinskih beta-laktamaz
PL3552017T3 (pl) Związki użyteczne jako inhibitory RIPK1
IL281742A (en) Novel compounds as nadph oxidase inhibitors
IL282041A (en) Egfr inhibitors for treating keratodermas
DK3863776T3 (da) Behandling af organisk affald
EP4096675C0 (en) COMPOSITIONS FOR THE TREATMENT OF LONG COVID